Febentel Plus (Fenbendazole 500mg + Ivermectin 25mg): Complete 2026 USA Guide
- Dr. Ryan Heals, Pharm.D.
- 2 days ago
- 12 min read
Updated: 1 day ago
The combination of Fenbendazole and Ivermectin has become the most searched antiparasitic cancer protocol in the world in 2026. Individually, each drug has a rapidly growing body of preclinical research and a large and growing collection of real-world anecdotal cases documenting remarkable responses in patients with advanced and treatment-resistant cancers. Together — at the doses used in Febentel Plus (Fenbendazole 500mg + Ivermectin 25mg) — they represent what integrative oncology researchers describe as a "polypharmacological" combination: two drugs that attack cancer through multiple independent and potentially synergistic mechanisms simultaneously.
As of May 2026, a publicly documented compilation maintained by cancer research advocates records more than 700 anecdotal cancer cases — across breast, lung, colorectal, pancreatic, prostate, glioblastoma, lymphoma, and head and neck cancers — reporting tumor regression, stabilization, or remission while using Fenbendazole and Ivermectin, often in combination with conventional therapy. A 2026 narrative synthesis applying pharmacovigilance methodology concluded that "the signal density, mechanistic plausibility, and cross-cancer recurrence pattern justify formal prospective evaluation under controlled conditions." A Phase I/II clinical trial evaluating Ivermectin combined with immune checkpoint inhibitors (ICONIC trial — NCT07487805) is currently active at multiple US cancer centers.
This complete guide covers exactly what Febentel Plus is, why this specific combination is attracting global attention, the 2026 protocols from both the Joe Tippens and Dr. William Makis frameworks, the complete scientific mechanism data, dosage schedules by cancer type, critical safety information including required monitoring, and how to buy genuine pharmaceutical-grade Febentel Plus (Fenbendazole 500mg + Ivermectin 25mg) online with free shipping to the USA.
At TheMedicineKart, we stock Febentel Plus — Fenbendazole 500mg + Ivermectin 25mg — in pharmaceutical-grade formulations sourced from WHO-GMP certified manufacturers, with fast USA-to-USA delivery and 50% off your first order using code MK50. Browse our full Anti-Worm and cancer protocol range at www.themedicinekart.com/anti-worm
What Is Febentel Plus?
Febentel Plus is a pharmaceutical-grade human combination formulation containing two of the most researched antiparasitic drugs currently under investigation for anticancer activity:
Detail | Fenbendazole Component | Ivermectin Component |
Active Ingredient | Fenbendazole | Ivermectin |
Dose per Tablet/Capsule | 500 mg | 25 mg |
Drug Class | Benzimidazole anthelmintic | Macrocyclic lactone antiparasitic |
Original Approval | Veterinary antiparasitic | Human antiparasitic (FDA 1987) |
Key Mechanism | Beta-tubulin binding, glucose inhibition, mTOR suppression | Chloride channel activation, PD-L1 modulation, mTOR inhibition |
Joe Tippens Protocol | Primary agent (222–500 mg) | Added in 2024–2026 updated protocols |
Dr. Makis Protocol | 444–1,500 mg daily | 1–2 mg/kg daily |
Cancer Research Status | Extensive preclinical; 700+ anecdotal cases | Phase I/II clinical trials active (ICONIC) |
Available at TheMedicineKart | ✓ Yes — 500 mg | ✓ Yes — 25 mg |
The combination of 500mg Fenbendazole with 25mg Ivermectin in a single formulation reflects the dosing pattern most commonly documented in the 2026 real-world case literature — particularly for patients following the intermediate cancer protocols developed by Dr. William Makis MD (McGill Medicine, 110+ peer-reviewed publications) and the updated 2026 version of the Joe Tippens protocol.
Why This Specific Combination? — The Synergy Rationale
The core scientific rationale for combining Fenbendazole and Ivermectin is that they attack cancer through independent but complementary mechanisms — meaning they target different cancer hallmarks simultaneously, making it significantly harder for cancer cells to develop resistance to any single pathway.
This principle — known as polypharmacology — is the same strategy that makes modern HIV treatment, tuberculosis therapy, and combination chemotherapy more effective than single-drug approaches. When two drugs with different targets are combined, cancer cells must simultaneously mutate or adapt across multiple independent pathways to survive — a statistically far less probable event than adapting to a single agent.
The 5 mechanisms where Fenbendazole and Ivermectin overlap or complement:
1. mTOR pathway suppression
— Both drugs independently suppress mTOR (mechanistic target of rapamycin), a central hub that drives cancer cell growth, proliferation, and survival. Dual mTOR suppression through two independent mechanisms produces stronger and more sustained pathway inhibition than either drug alone.
2. Glucose metabolism disruption
— Fenbendazole blocks GLUT1 glucose transporters and hexokinase. Ivermectin disrupts mitochondrial Complex I. Together they attack the Warburg effect (cancer's glucose dependency) from two independent angles — simultaneously blocking glucose entry and disrupting its processing.
3. Microtubule disruption
— Fenbendazole binds beta-tubulin and destabilizes microtubules in cancer cells (the same mechanism as taxane chemotherapy). Ivermectin has been shown to further disrupt spindle assembly during mitosis. Combined, they produce a more complete blockade of cancer cell division.
4. Immune system modulation
— Ivermectin uniquely downregulates PD-L1 — the immune checkpoint protein that cancer cells use to hide from the immune system. By reducing PD-L1 expression, Ivermectin effectively "unmasks" cancer cells and makes them visible to T-cells. This is the mechanistic basis for combining Ivermectin with immune checkpoint inhibitors (such as pembrolizumab / Keytruda) in the ICONIC clinical trial. Fenbendazole contributes via NLRP3 inflammasome activation, which stimulates innate immune response against tumor cells.
5. Apoptosis induction
— Both drugs independently activate p53 (the tumor suppressor protein) and trigger programmed cell death (apoptosis) pathways in cancer cells. Combined, they produce stronger and more consistent apoptosis signals across a wider range of cancer cell types.
The 2026 head and neck cancer case series
— published as a narrative synthesis integrating mechanistic studies, preclinical oncology literature, and publicly available case reports — described Fenbendazole and Ivermectin's combined profile as demonstrating "multi-targeted anticancer effects including disruption of microtubule dynamics, inhibition of oncogenic signaling pathways (Wnt/β-catenin, PI3K/Akt), modulation of tumor metabolism, and induction of apoptosis — especially relevant where molecular heterogeneity and adaptive resistance frequently undermine single-target therapies."
The Complete 2026 Protocol Framework
Two primary protocol frameworks guide the clinical use of Fenbendazole + Ivermectin combinations in 2026. Here is a complete, evidence-sourced breakdown of both:
Framework 1 — Updated Joe Tippens Protocol (2026 Version)
The original Joe Tippens Protocol (222mg Fenbendazole + Curcumin + CBD + Vitamin E) has been significantly expanded and updated based on five years of real-world case accumulation and the addition of Ivermectin as a combination partner in 2024–2026.
Component | Standard Protocol | Aggressive Cancer Protocol |
Fenbendazole | 222–444 mg daily | 444–500 mg daily (or 1,000 mg) |
Ivermectin | 12–24 mg daily (6 days/week) | 1 mg/kg/day daily |
Bioavailable Curcumin | 600 mg twice daily | 600 mg twice daily |
CBD Oil | 25 mg daily | 100 mg daily |
Vitamin E Succinate | 400–800 IU daily | 800 IU daily |
Vitamin D3 | 5,000–10,000 IU daily | 10,000–20,000 IU daily |
Berberine (enhanced) | 500 mg daily | 500 mg twice daily |
Melatonin (high-dose) | 20–60 mg nightly | 100–180 mg nightly |
Schedule | 3 days on / 4 days off (Fenbendazole) | Daily (continuous) |
Duration | Minimum 3 months; assess at 3-month intervals | Until NED (No Evidence of Diseas |
Note on Febentel Plus dosing in this protocol:
Each tablet of Febentel Plus provides 500mg Fenbendazole + 25mg Ivermectin. For a 75–80kg adult patient on the standard protocol, one Febentel Plus tablet daily provides both the Fenbendazole dose and a meaningful Ivermectin dose within a single convenient formulation — significantly simplifying the protocol.
Framework 2 — Dr. William Makis Protocol (2026)
Dr. William Makis MD (McGill Medicine, 110+ peer-reviewed publications) has developed distinct protocol tiers based on cancer type and aggressiveness:
Protocol Tier | Cancer Types | Fenbendazole Dose | Ivermectin Dose | Schedule |
Standard | Prostate, thyroid, early breast, colorectal | 444–500 mg daily | 0.5–1 mg/kg/day | Daily with fatty meal |
Intermediate | Lung, bladder, ovarian, uterine, kidney | 500–1,000 mg daily | 1–1.5 mg/kg/day | Daily continuous |
Aggressive | Lymphoma, leukemia, pancreatic, GBM, TNBC, sarcoma | 1,000–1,500 mg daily | 1.5–2 mg/kg/day | Daily until NED |
Turbo Cancer | Stage 4, rapidly progressing, conventional failures | Up to 1,500 mg daily | 2 mg/kg/day + topical DMSO | Daily + topical |
Dr. Makis 2026 dosing rules:
- Always take with a high-fat meal — dramatically improves absorption of both Fenbendazole and Ivermectin (up to 5x increase in bioavailability)
- Combine with intermittent fasting or ketogenic diet — Dr. Makis reports 3–5x synergy enhancement from metabolic restriction
- Monitor liver enzymes (AST, ALT) and kidney function (creatinine, eGFR) every 4–6 weeks
- Monitor CBC (complete blood count) every 4–6 weeks
- Human pharmaceutical-grade tablets only — never veterinary formulations
- Duration: minimum 3–6 months for standard cases; continue until NED confirmed, then taper under medical supervision
The ICONIC trial (NCT07487805):
A Phase I/II study evaluating Ivermectin combined with immune checkpoint inhibitors is currently actively recruiting at multiple US cancer centers — representing the first formalized human trial of Ivermectin in combination cancer immunotherapy. Additionally, a Cedars-Sinai Medical Center Phase I/II trial (Yuan Yuan et al., 2025–2026) is evaluating Ivermectin safety and efficacy profiles in cancer patients.
The 2026 Evidence Landscape — What Research Actually Shows
It is essential to present the 2026 evidence base honestly — both what is genuinely compelling and what remains unproven:
The anecdotal evidence — 700+ documented cases:
A publicly accessible compilation documents more than 700 anecdotal cancer cases reporting tumor regression, stabilization, or remission while using Fenbendazole, Mebendazole, and/or Ivermectin. A 2026 pharmacovigilance analysis of this dataset concluded: "The dataset does not constitute mainstream clinical evidence. However, the signal density, mechanistic plausibility, and cross-cancer recurrence pattern justify formal prospective evaluation under controlled conditions."
Active clinical trials as of May 2026:
Trial | Drug | Cancer Type | Status |
ICONIC (NCT07487805) | Ivermectin + checkpoint inhibitor | Multiple cancers | Phase I/II — recruiting |
NCT05318469 | Ivermectin + immunotherapy | Breast cancer | Phase II — recruiting |
NCT02366884 | Metabolic therapy + Ivermectin | Advanced cancers | Completed |
NCT03925662 | Mebendazole as adjuvant | Stage 4 colon cancer | Phase 2/3 — recruiting |
NCT03628079 | Mebendazole | GI cancers | Phase II — completed |
Anticancer mechanisms confirmed in peer-reviewed preclinical research:
Fenbendazole (12 confirmed mechanisms per Dr. Makis 2026 review):
- Beta-tubulin depolymerization — same mechanism as taxane chemotherapy
- GLUT1 glucose transporter blockade — starves cancer cells of fuel
- Hexokinase II inhibition — blocks glycolytic enzyme critical for tumor metabolism
- mTOR suppression — reduces cancer cell growth and proliferation signaling
- p53 reactivation — restores tumor suppressor function in cancer cells
- NLRP3 inflammasome activation — stimulates innate immune response
- Autophagy induction — triggers cellular self-digestion in cancer cells
- Wnt/β-catenin pathway inhibition — relevant in colorectal and breast cancers
- PI3K/Akt pathway inhibition — broad cancer signaling pathway blockade
- Ferroptosis induction — iron-dependent programmed cell death
- Angiogenesis inhibition — reduces tumor blood supply formation
- Apoptosis via mitochondrial pathway — direct cancer cell death signaling
Ivermectin (key anticancer mechanisms):
- PD-L1 downregulation — immune checkpoint removal; "unmasks" cancer for T-cells
- Chloride channel disruption in cancer cell membranes
- mTOR pathway inhibition — synergistic with Fenbendazole
- PAK1 kinase inhibition — relevant in breast, colon, and pancreatic cancers
- Mitochondrial Complex I disruption — complementary to Fenbendazole glucose blockade
- SIN3A/STAT3 pathway modulation — epigenetic cancer signaling interference
- Macrophage M2-to-M1 repolarization — converts tumor-promoting immune cells to tumor-killing ones
What the research does NOT yet show:
No phase III randomized controlled trial has confirmed Fenbendazole or Ivermectin as effective cancer treatments in humans. Neither drug is FDA-approved for any cancer indication. The anticancer concentrations demonstrated in laboratory cell culture studies are often significantly higher than what standard oral dosing achieves in human plasma. The 700+ anecdotal case reports, while numerous and mechanistically plausible, are subject to selection bias, reporting bias, and confounding from concurrent conventional treatments. Anyone using Febentel Plus as part of a cancer protocol must do so under medical supervision with regular clinical monitoring.
Dosage Guide for Febentel Plus — By Protocol Level
Each Febentel Plus tablet contains: **Fenbendazole 500mg + Ivermectin 25mg
Protocol Level | Febentel Plus Dose | Additional Fenbendazole | Additional Ivermectin | Schedule |
Standard (prophylaxis / early cancer) | 1 tablet (500 mg FBZ + 25 mg IVM) | None | None | 3 days on / 4 days off |
Intermediate | 1 tablet daily | Optional +500 mg FBZ | None | Daily with fatty meal |
Aggressive cancer | 1–2 tablets daily | +500 mg–1,000 mg FBZ | +12 mg IVM if weight >80 kg | Daily continuous |
Turbo / Stage 4 | 2 tablets daily | +500 mg FBZ | Weight-adjusted IVM | Daily — medical supervision required |
Always take Febentel Plus with a high-fat meal
— both Fenbendazole and Ivermectin are highly lipophilic (fat-soluble) and their oral bioavailability increases dramatically with dietary fat. Clinical data shows up to a 5x increase in peak plasma concentration when taken with a fatty meal versus fasted.
Maximum daily doses from documented protocols:
- Fenbendazole: up to 1,500mg/day (Makis aggressive protocol); 500mg most common standard dose
- Ivermectin: up to 2 mg/kg/day (Makis); 25mg (one Febentel Plus tablet) covers most standard protocol requirements for adults up to approximately 80kg
Safety, Side Effects, and Required Monitoring
General safety profile:
Both Fenbendazole and Ivermectin have well-established favorable safety profiles across decades of use. At standard Joe Tippens protocol doses (222–500mg FBZ, 12–25mg IVM), serious adverse events are rare. At Makis aggressive protocol doses (1,000–1,500mg FBZ, 1–2 mg/kg IVM), monitoring becomes essential.
Common side effects at standard doses:
- Mild nausea — particularly in first 1–2 weeks; taking with food resolves in most cases
- Mild fatigue — transient, often during the first week as the body adapts
- Temporary die-off reaction (Jarisch-Herxheimer-like) — some patients report transient worsening of symptoms as antiparasitic effects begin; typically resolves within 72 hours
- Mild dizziness — more common with higher Ivermectin doses; take with fatty food and remain seated after dosing
Critical safety concern — Liver toxicity (hepatotoxicity):
This is the most important documented safety risk with Fenbendazole + Ivermectin combination use, particularly at higher doses or with continuous daily use without cycling. Multiple published case reports document:
- Transient elevation of liver enzymes (AST/ALT) — most common; usually resolves with dose reduction or temporary break
- Severe acute hepatotoxicity — rare but documented, particularly with daily continuous use at doses above 1,000mg Fenbendazole without liver monitoring
Mandatory monitoring protocol for anyone using Febentel Plus:
- Baseline: Complete liver function panel (AST, ALT, bilirubin, alkaline phosphatase), CBC, kidney function (creatinine, eGFR) before starting
- Every 4–6 weeks during active use: Repeat liver function panel + CBC + kidney function
- If AST or ALT rises above 3x the upper limit of normal — reduce dose immediately and consult your physician
- If AST or ALT rises above 5x the upper limit of normal — stop Febentel Plus and seek urgent medical evaluation
Who should use extra caution or consult a physician first:
- Anyone with pre-existing liver conditions or hepatic impairment
- Anyone currently undergoing chemotherapy or immunotherapy — inform your oncologist before adding Febentel Plus; drug interactions with chemotherapy agents processed through CYP450 pathways are possible
- Patients with Loa loa (loiasis) — high microfilariae levels combined with Ivermectin can trigger serious neurological reactions
- Pregnant or breastfeeding women — insufficient safety data for either drug in pregnancy; not recommended
- Anyone on warfarin — both drugs may affect anticoagulant activity; INR monitoring required
How to Buy Febentel Plus Online in the USA
Step 1:
Consult your integrative oncologist, primary care physician, or a longevity-focused healthcare provider before starting any antiparasitic cancer protocol. Discuss your specific cancer type, current conventional treatments, and any medications you are taking that may interact.
Step 2:
Establish baseline bloodwork — liver function panel, CBC, and kidney function — before your first dose.
Step 3:
Visit Themedicinekart and select Febentel Plus (Fenbendazole 500mg + Ivermectin 25mg). All products are sourced from WHO-GMP certified pharmaceutical manufacturers — pharmaceutical-grade human formulations, not veterinary products.
Step 4:
Apply code MK50 for 50% off your first order. Free shipping on all orders above $199. USA-to-USA delivery within 4 business days in fully discreet, plain packaging.
Also available separately at TheMedicineKart:
- Fenbendazole (Wormentel) — standalone at 100mg, 200mg, 500mg strengths
- Ivermectin — standalone at 6mg, 12mg, 15mg, 20mg, 40mg strengths
- Mebendazole — for triple benzimidazole protocols
- Wormentel Duo 156 — Fenbendazole + Ivermectin combination in different ratio
For related reading, see our complete Fenbendazole (Wormentel) guide, Ivermectin for Scabies and Antiparasitic guide, and Mebendazole Cancer Research guide on the TheMedicineKart blog.
Frequently Asked Questions
What makes Febentel Plus different from taking Fenbendazole and Ivermectin separately?
Febentel Plus provides both drugs in a single pharmaceutical-grade tablet — simplifying compliance, ensuring consistent dosing, and eliminating the risk of sourcing multiple separate products from different suppliers of varying quality. Each tablet delivers 500mg of Fenbendazole and 25mg of Ivermectin in the exact ratio most commonly documented in 2026 intermediate cancer protocols. For patients on the standard Joe Tippens protocol or the Dr. Makis standard-tier protocol, a single Febentel Plus tablet with a fatty meal covers both drugs in one step.
Why is the Fenbendazole + Ivermectin combination considered more effective than either drug alone?
The combination targets cancer through more independent pathways simultaneously — a strategy called polypharmacology. Fenbendazole primarily disrupts structural cell division (microtubules) and metabolism (glucose), while Ivermectin uniquely targets the immune checkpoint protein PD-L1, effectively unmasking cancer cells so the immune system can attack them. This immunological mechanism is something Fenbendazole cannot achieve on its own. When cancer cells develop resistance to one agent's mechanism, the other agent's entirely different mechanism continues to exert pressure — making combined resistance far less likely than resistance to a single drug.
Is 25mg Ivermectin safe? Most protocols use weight-based dosing.
At 25mg, Ivermectin is within the weight-adjusted safe range for adults weighing approximately 70–80kg at 0.3–0.35 mg/kg — which is well within the standard antiparasitic dosing range. For the higher-dose Makis protocols using 1–2 mg/kg daily, 25mg would be appropriate for individuals weighing approximately 12–25kg, meaning additional Ivermectin would be required for most adults. For standard and intermediate protocols, 25mg daily (one Febentel Plus tablet) represents a safe, well-documented starting dose. Always calculate your weight-based dose and discuss with a physician before escalating.
How long does it take to see results with Febentel Plus?
Based on the documented anecdotal case literature, some patients report detectable changes in tumor markers or imaging within 3–6 months of consistent protocol use. Joe Tippens reported a clear PET scan after approximately 3 months. However, individual responses vary enormously by cancer type, stage, concurrent treatments, metabolic status, and protocol compliance. Anyone using Febentel Plus alongside conventional cancer treatment should maintain regular oncology follow-up with imaging and tumor marker monitoring to objectively assess response. Give any protocol a minimum of 3 months before evaluating effectiveness.
Can I take Febentel Plus alongside chemotherapy or immunotherapy?
Many patients in the documented case literature have used Fenbendazole and Ivermectin alongside conventional treatments. The combination is particularly interesting alongside immunotherapy — Ivermectin's PD-L1 downregulation works through a mechanism that theoretically enhances the activity of PD-1/PD-L1 immune checkpoint inhibitors (pembrolizumab, nivolumab, atezolizumab), which is the scientific basis for the ICONIC clinical trial. However, drug interactions with specific chemotherapy agents processed through the CYP450 enzyme system are possible with both Fenbendazole and Ivermectin. It is absolutely essential to inform your oncologist before adding Febentel Plus to any conventional cancer treatment regimen.
Comments